RU93016575A - ANTIHYPOXIC PRODUCT - Google Patents

ANTIHYPOXIC PRODUCT

Info

Publication number
RU93016575A
RU93016575A RU93016575/14A RU93016575A RU93016575A RU 93016575 A RU93016575 A RU 93016575A RU 93016575/14 A RU93016575/14 A RU 93016575/14A RU 93016575 A RU93016575 A RU 93016575A RU 93016575 A RU93016575 A RU 93016575A
Authority
RU
Russia
Prior art keywords
antihypoxic
tissues
product
relates
hydrochloride
Prior art date
Application number
RU93016575/14A
Other languages
Russian (ru)
Other versions
RU2072845C1 (en
Inventor
С.Н. Ермольев
А.В. Белоусов
Е.М. Луговая
Original Assignee
С.Н. Ермольев
А.В. Белоусов
Е.М. Луговая
Filing date
Publication date
Application filed by С.Н. Ермольев, А.В. Белоусов, Е.М. Луговая filed Critical С.Н. Ермольев
Priority to RU93016575A priority Critical patent/RU2072845C1/en
Priority claimed from RU93016575A external-priority patent/RU2072845C1/en
Publication of RU93016575A publication Critical patent/RU93016575A/en
Application granted granted Critical
Publication of RU2072845C1 publication Critical patent/RU2072845C1/en

Links

Claims (1)

Изобретение относится к медицине, а именно к фармакологии и касается лекарственных средств, проявляющих антигипоксическую активность. Цель - повышение эффективности лечения состояний, сопровождающихся наличием выраженной гипоксии, путем усиления обменных процессов в тканях. Для этого в качестве антигипоксанта предлагается применение гидрохлорида 6,7-диметокси-1-(3,4-диметоксибензил)- изохинолина (папаверина гидрохлорида). Препарат обладает выраженным продолжительным антигипоксическим действием на ткани головного мозга и пародонта, превосходящим на 20 - 40% подобное действие аналогов. Побочных явлений не отмечается.The invention relates to medicine, namely to pharmacology, and relates to drugs exhibiting antihypoxic activity. The goal is to increase the effectiveness of the treatment of conditions accompanied by the presence of severe hypoxia by enhancing metabolic processes in the tissues. For this, the use of 6,7-dimethoxy-1- (3,4-dimethoxybenzyl) -isoquinoline hydrochloride (papaverine hydrochloride) is proposed as an antihypoxant. The drug has a pronounced long-lasting antihypoxic effect on the tissues of the brain and periodontium, which is 20 - 40% higher than that of analogues. Side effects are not noted.
RU93016575A 1993-03-29 1993-03-29 Agent for prophylaxis and treatment of parodontium hypoxia RU2072845C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU93016575A RU2072845C1 (en) 1993-03-29 1993-03-29 Agent for prophylaxis and treatment of parodontium hypoxia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU93016575A RU2072845C1 (en) 1993-03-29 1993-03-29 Agent for prophylaxis and treatment of parodontium hypoxia

Publications (2)

Publication Number Publication Date
RU93016575A true RU93016575A (en) 1996-11-10
RU2072845C1 RU2072845C1 (en) 1997-02-10

Family

ID=20139527

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93016575A RU2072845C1 (en) 1993-03-29 1993-03-29 Agent for prophylaxis and treatment of parodontium hypoxia

Country Status (1)

Country Link
RU (1) RU2072845C1 (en)

Similar Documents

Publication Publication Date Title
PT1002792E (en) 2-AMINOPROPANE-1,3-DIOLE COMPOUNDS, ITS MEDICINAL AND INTERMEDIATE USE OF THE SYMPTOMS OF THE SAME
PT97638A (en) METHOD FOR THE PREPARATION OF PEPTIDICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
RU2001116077A (en) A method for the treatment of cerebral ischemia, as well as the use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischemia
RU93004793A (en) HINAZOLIN DERIVATIVES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS
JP2578001B2 (en) Anti-dementia drug
TW197423B (en)
CA2157792A1 (en) N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists
GB8807922D0 (en) Isoquinoline compound & process for preparation thereof
ATE409028T1 (en) MEDICATIONS FOR THE TREATMENT OF NERVE DISEASES
ATE265851T1 (en) TREATMENT OF DISEASES CAUSED BY CYTOKINE GROWTH FACTOR
RU93016575A (en) ANTIHYPOXIC PRODUCT
RU94017849A (en) Medicinal preparation for neurocorrection
Giménez‐Roldán et al. Effectiveness of Clonazepan in Startle‐induced Seizures
DK526087A (en) ANTICONVULSIVE AMINO ACID DERIVATIVES
MX9405209A (en) USE OF N- (PIRIDINYL) -1H-INDOL-1-AMINES IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS.
RU92004569A (en) PHARMACEUTICAL PRODUCT OF ANTI-STRESS, STRESS-PROTECTIVE AND NOOTROPIC ACTION
Hawkes N-BENZYL-β-CHLOROPROPIONAMIDE (HIBICON®): A New Approach to Anticonvulsant Therapy
IL83586A (en) Acylated aminoalkyl and hydroxyalkyl substituted spirocondensed hexahydroarylquinolizines and peripheral alpha2 adrenoceptor antagonist pharmaceutical compositions containing them
KR920703067A (en) L-α-glycerophoryl-D-myo-inositol for the treatment of peripheral neurological and brain diseases
Moe et al. The effects of tranquilizers on myocardial metabolism
RU2184542C2 (en) 1-phenyl-1-cyclopentyl-4-piperidino-2 butin-1-ola hydrochloride possessing activity in treating and preventing parkinsonism
Alexander et al. Comparison of anticonvulsive properties of eboracin and phenytoin in mice
RU95116290A (en) APPLICATION OF 5-MORPHOLINO-3- (4-CHLORBENZYLIDENAMINE) -2-OXAZOLIDINONE, PHARMACEUTICAL COMPOSITION ON ITS BASIS, METHOD OF TREATMENT
EP0375471A3 (en) Use of 1,2,3,4-tetrahydro-acridines in the treatment of aids, and compounds
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders